PCI Biotech Shares Owned By Insiders vs. Gross Profit
| PCIB Stock | NOK 1.40 0.01 0.71% |
For PCI Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PCI Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PCI Biotech Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PCI Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PCI Biotech Holding over time as well as its relative position and ranking within its peers.
PCI |
PCI Biotech Holding Gross Profit vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining PCI Biotech's current stock value. Our valuation model uses many indicators to compare PCI Biotech value to that of its competitors to determine the firm's financial worth. PCI Biotech Holding is considered to be number one stock in shares owned by insiders category among its peers. It also is considered to be number one stock in gross profit category among its peers fabricating about 196,215 of Gross Profit per Shares Owned By Insiders. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PCI Biotech's earnings, one of the primary drivers of an investment's value.PCI Gross Profit vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
PCI Biotech |
| = | 31.97 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
PCI Biotech |
| = | 6.27 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
PCI Gross Profit Comparison
PCI Biotech is currently under evaluation in gross profit category among its peers.
PCI Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in PCI Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PCI Biotech will eventually generate negative long term returns. The profitability progress is the general direction of PCI Biotech's change in net profit over the period of time. It can combine multiple indicators of PCI Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people.
PCI Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on PCI Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PCI Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PCI Biotech's important profitability drivers and their relationship over time.
Use PCI Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PCI Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PCI Biotech will appreciate offsetting losses from the drop in the long position's value.PCI Biotech Pair Trading
PCI Biotech Holding Pair Trading Analysis
The ability to find closely correlated positions to PCI Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PCI Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PCI Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PCI Biotech Holding to buy it.
The correlation of PCI Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PCI Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PCI Biotech Holding moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PCI Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your PCI Biotech position
In addition to having PCI Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Funds Thematic Idea Now
Precious Metals Funds
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in PCI Stock
To fully project PCI Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PCI Biotech Holding at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PCI Biotech's income statement, its balance sheet, and the statement of cash flows.